Session » Health Services Research – ACR/ARP Poster III

Date: Monday, November 18, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 1930

Clinical Significance of Positive ENA Testing in ANA-Negative Patients: A Retrospective Analysis of Rheumatologic Diagnoses

10:30AM-12:30PM: Abstract Number: 1932

Effects of Clinical Decision Support on Transition Readiness Assessment in Pediatric Rheumatology

10:30AM-12:30PM: Abstract Number: 1942

Electronic Health Literacy and Its Association with Disease Activity in RMD Patients – a Cross Sectional Study

10:30AM-12:30PM: Abstract Number: 1944

Enhancing Rheumatology Consultations with AI-Powered Triage: The ReumAI Pilot Study

10:30AM-12:30PM: Abstract Number: 1938

Evaluating Diagnostic Performance of Mycobacterium Tuberculosis Derived Cell-free DNA (CF-DNA) for Diagnosis of Osteoarticular Tuberculosis (OATB): A Novel Method

10:30AM-12:30PM: Abstract Number: 1954

Examination of Rehabilitation Referrals from Rheumatology Practices for Adults with Rheumatoid Arthritis in the RISE Registry: A Feasibility and Descriptive Study

10:30AM-12:30PM: Abstract Number: 1931

Health System Improvement in Appropriate Test Utilization Involving ANA Testing in the Inpatient and Outpatient Setting

10:30AM-12:30PM: Abstract Number: 1949

Implementation of Pharmacist-Led Comprehensive Medication Management for Puerto Ricans with Rheumatic Diseases

10:30AM-12:30PM: Abstract Number: 1952

Interest in Clinical Trial Participation Among People with Lupus: Results from the Research Accelerated by You (RAY) Registry

10:30AM-12:30PM: Abstract Number: 1934

Knee Symptom Phenotyping Incorporating Pain and Function: A Multiple-Trajectory Modeling-Based Study Using Data from the Osteoarthritis Initiative (OAI)

10:30AM-12:30PM: Abstract Number: 1941

No Show QI at Hoxworth Rheumatology Clinic: Evaluating the Impact of Live Telephone Calls Combined with Automated Reminders

10:30AM-12:30PM: Abstract Number: 1947

Optimizing Osteoarthritis Care Through Clinical and Community Partnership: Results of an Exploratory Trial

10:30AM-12:30PM: Abstract Number: 1951

Patient-Reported Barriers to Care Across Pediatric Rheumatology Patients at a Tertiary Academic Medical Center

10:30AM-12:30PM: Abstract Number: 1939

Patient’s Satisfaction with a Telerheumatology Program in a Remote Rural Area of Northern Pakistan

10:30AM-12:30PM: Abstract Number: 1936

Referral and Diagnostic Delays of Patients with Chronic Inflammatory Rheumatic Diseases: A Cross-sectional Study in Eight Countries

10:30AM-12:30PM: Abstract Number: 1946

Shaping the Future of the National Musculoskeletal (MSK) Triage Initiative: Exploring the Impact of a Hybrid Model (Virtual and Face to Face) of MSK Triage

10:30AM-12:30PM: Abstract Number: 1950

Telehealth Physical Therapy Intervention to Increase Physical Activity in Adults with Knee OA: The Delaware PEAK Randomized Controlled Trial

10:30AM-12:30PM: Abstract Number: 1933

Telemedicine for Under-resourced Patients with Systemic Lupus Erythematosus: A Qualitative Study Exploring the Views and Experiences of Patients and Rheumatology Health Care Professionals

10:30AM-12:30PM: Abstract Number: 1945

The Bridge to Adult Care from Childhood for Young Adults with Rheumatic Disease (BACC YARD) Program, a Pediatric-to-Adult Rheumatology Transition Program: 2024 Updates

10:30AM-12:30PM: Abstract Number: 1953

The National Trend of Using Prescription Immunosuppressives

10:30AM-12:30PM: Abstract Number: 1948

The Rheumatology Physician Assistant/Associate Workforce

10:30AM-12:30PM: Abstract Number: 1940

Timely Initiation of Steroid Sparing Therapy in Uveitis Patients – a Quality Improvement Initiative

10:30AM-12:30PM: Abstract Number: 1935

Timely Referral of Patients with Inflammatory Rheumatic Diseases to Rheumatology: Validation of a Referral Algorithm with Frontline Physicians

10:30AM-12:30PM: Abstract Number: 1929

Use of Digital Health Tools for Health Promotion Among Individuals with Rheumatologic Diseases in the United States

10:30AM-12:30PM: Abstract Number: 1928

Utilization of Rapid Telehealth Visits by Advanced Practice Providers for New Patients Referred to a Large Academic Practice with Low Suspicion for Rheumatologic Disease

10:30AM-12:30PM: Abstract Number: 1943

Virtual Rheumatology in the Real World: Use of Telemonitoring to Optimize the Management of Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1937

Wellness and Burnout Among Pediatric Rheumatologists in North America- A 2024 CARRA Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].